Salcedo M et al. |
The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. |
2007 |
Apoptosis |
pmid:17191124
|
Sánchez AM et al. |
Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. |
2008 |
Eur. J. Pharmacol. |
pmid:18343365
|
Pruett ST et al. |
Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols. |
2008 |
J. Lipid Res. |
pmid:18499644
|
Baird RD et al. |
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. |
2009 |
Mol. Cancer Ther. |
pmid:19509256
|
Bertea M et al. |
Deoxysphingoid bases as plasma markers in diabetes mellitus. |
2010 |
Lipids Health Dis |
pmid:20712864
|
Vilar E et al. |
A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. |
2012 |
Invest New Drugs |
pmid:20820909
|
Schöffski P et al. |
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. |
2011 |
Cancer Chemother. Pharmacol. |
pmid:21465314
|
Rotthier A et al. |
Characterization of two mutations in the SPTLC1 subunit of serine palmitoyltransferase associated with hereditary sensory and autonomic neuropathy type I. |
2011 |
Hum. Mutat. |
pmid:21618344
|
Malik G et al. |
Aziridines from intramolecular alkene aziridination of sulfamates: reactivity toward carbon nucleophiles. application to the synthesis of spisulosine and its fluoro analogue. |
2011 |
J. Org. Chem. |
pmid:21812488
|
Merrill AH |
Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. |
2011 |
Chem. Rev. |
pmid:21942574
|